# A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Lower Blood Sugar in People With Type 2 Diabetes

Study · id `cardio:ct-nct06326047` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06326047](<https://clinicaltrials.gov/study/NCT06326047>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06326047

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 299 participants.

## Technical summary

Registry record NCT06326047. Randomized; quadruple masking; primary purpose treatment. Start 2024-03-18 (actual); primary completion 2025-09-19 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 299 participants (enrolled count; ClinicalTrials.gov record NCT06326047, source copy `cardio:ctgov-nct06326047-2026-09-21`, retrieved 2026-10-26)
- Started: 2024-03-18 (actual) (ClinicalTrials.gov record NCT06326047, source copy `cardio:ctgov-nct06326047-2026-09-21`, retrieved 2026-10-26)
- Primary completion: 2025-09-19 (actual) (ClinicalTrials.gov record NCT06326047, source copy `cardio:ctgov-nct06326047-2026-09-21`, retrieved 2026-10-26)
- Completion: 2025-10-13 (actual) (ClinicalTrials.gov record NCT06326047, source copy `cardio:ctgov-nct06326047-2026-09-21`, retrieved 2026-10-26)
- Countries: United States; Australia; Canada; India; Japan; South Africa; South Korea (ClinicalTrials.gov record NCT06326047, source copy `cardio:ctgov-nct06326047-2026-09-21`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06326047-2026-09-21`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Lower Blood Sugar in People With Type 2 Diabetes
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): NNC0519-0130
- Intervention (Drug): Placebo
- Intervention (Drug): Trizepatide
- Lead sponsor: Novo Nordisk A/S
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Novo Nordisk (`cardio:novo-nordisk`)

## Provenance

Content hash: 521c3228e7c596c1f1d08ada857bea55ba5b1c2eb7c95aa330bf1d50c603365c
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
